BIS-targeted decongestive treatment maintains outcome benefits for up to 3 years after TAVR in patients with severe aortic stenosis and volume overload.
Does BIS-targeted decongestive treatment improve outcomes in patients with severe aortic stenosis and volume overload after TAVR?
BIS-targeted decongestive treatment provides persistent outcome benefits up to 3 years post-TAVR in patients with severe AS and volume overload.
Absolute Event Rate: 0% vs 0%
In patients with severe AS and VO, outcome benefits of BIS-targeted decongestive treatment persist up to 3 years after TAVR.
Autherith et al. (Wed,) reported a other. BIS-targeted decongestive treatment maintains outcome benefits for up to 3 years after TAVR in patients with severe aortic stenosis and volume overload.